proline has been researched along with molnupiravir in 14 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 14 (100.00) | 2.80 |
Authors | Studies |
---|---|
Couzin-Frankel, J | 1 |
Parums, DV | 2 |
Borio, LL; Bright, RA; Emanuel, EJ | 1 |
Del Rio, C; Gandhi, RT; Malani, PN | 1 |
Misra, A; Singh, A; Singh, AK; Singh, R | 1 |
Kozlov, M | 1 |
André, E; Chiu, W; De Jonghe, S; Jochmans, D; Leyssen, P; Maes, P; Neyts, J; Raymenants, J; Slechten, B; Vangeel, L | 1 |
Bajaj, SS; Stanford, FC | 1 |
Chen, C; Cheng, Y; Feng, Z; Mao, Q; Tang, J; Wang, C; Wang, M; Wen, W; Wu, Q; Zhang, X; Zhou, M; Zhou, X | 1 |
Ledford, H | 1 |
Adachi, E; Chong, Z; Diamond, MS; Douek, DC; Duong, C; Fujisaki, S; Furusawa, Y; Godbole, S; Gordon, A; Hagihara, M; Halfmann, PJ; Hasegawa, H; Hattori, SI; Hojo, M; Iida, S; Imai, M; Ito, M; Iwatsuki-Horimoto, K; Kawaoka, Y; Kiso, M; Koga, M; Kuroda, M; Larson, D; Li, R; Liu, Y; Loeber, S; Maeda, K; Maemura, T; Mitamura, K; Mitsuya, H; Murakami, J; Ohmagari, N; Okuda, M; Ozono, S; Saito, M; Sakai-Tagawa, Y; Sato, T; Suzuki, T; Takashita, E; Tsutsumi, T; Ueki, H; Ujie, M; Uraki, R; Valdez, R; Wang, Z; Watanabe, S; Wright, R; Yamamoto, S; Yamayoshi, S; Yasuhara, A; Yotsuyanagi, H | 1 |
1 review(s) available for proline and molnupiravir
Article | Year |
---|---|
Efficacy and safety of three new oral antiviral treatment (molnupiravir, fluvoxamine and Paxlovid) for COVID-19:a meta-analysis.
Topics: Antiviral Agents; COVID-19 Drug Treatment; Cytidine; Drug Combinations; Fluvoxamine; Humans; Hydroxylamines; Lactams; Leucine; Nitriles; Proline; Ritonavir; SARS-CoV-2 | 2022 |
1 trial(s) available for proline and molnupiravir
Article | Year |
---|---|
An updated practical guideline on use of molnupiravir and comparison with agents having emergency use authorization for treatment of COVID-19.
Topics: Adenosine Monophosphate; Aged; Alanine; Animals; Antiviral Agents; COVID-19; COVID-19 Drug Treatment; COVID-19 Vaccines; Cytidine; Double-Blind Method; Drug Approval; Drug Combinations; Female; Hospitalization; Humans; Hydroxylamines; Lactams; Leucine; Male; Middle Aged; Nitriles; Proline; Ritonavir; SARS-CoV-2; Severity of Illness Index; Treatment Outcome | 2022 |
12 other study(ies) available for proline and molnupiravir
Article | Year |
---|---|
Antiviral pills could change pandemic's course.
Topics: Antiviral Agents; Clinical Trials as Topic; Coronavirus Protease Inhibitors; COVID-19; COVID-19 Drug Treatment; Cytidine; Humans; Hydroxylamines; Lactams; Leucine; Nitriles; Proline; Ritonavir; SARS-CoV-2; Tablets | 2021 |
Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Patients.
Topics: Administration, Oral; Antibodies, Monoclonal; Antiviral Agents; COVID-19 Drug Treatment; Cytidine; Drug Approval; Drug Repositioning; Humans; Hydroxylamines; Lactams; Leucine; Nitriles; Proline; Ritonavir; SARS-CoV-2; United States; United States Food and Drug Administration | 2022 |
A National Strategy for COVID-19 Medical Countermeasures: Vaccines and Therapeutics.
Topics: Antiviral Agents; COVID-19; COVID-19 Drug Treatment; COVID-19 Testing; COVID-19 Vaccines; Cytidine; Drug Combinations; Endemic Diseases; Humans; Hydroxylamines; Immunization Schedule; Lactams; Leucine; Nitriles; Population Surveillance; Proline; Ritonavir; SARS-CoV-2; United States | 2022 |
COVID is here to stay: countries must decide how to adapt.
Topics: Adaptation, Psychological; Adult; Child; COVID-19; COVID-19 Drug Treatment; COVID-19 Vaccines; Cytidine; Drug Combinations; Endemic Diseases; Humans; Hydroxylamines; Immunity, Herd; Immunization, Secondary; International Cooperation; Lactams; Leucine; Nitriles; Physical Distancing; Proline; Reinfection; Ritonavir; SARS-CoV-2; Social Change; South Africa | 2022 |
COVID-19 Therapeutics for Nonhospitalized Patients.
Topics: Adenosine Monophosphate; Alanine; Antibodies, Monoclonal, Humanized; Antibodies, Neutralizing; Antiviral Agents; Child; COVID-19 Drug Treatment; Cytidine; Drug Combinations; Female; Health Care Rationing; Humans; Hydroxylamines; Lactams; Leucine; Nitriles; Outpatients; Pregnancy; Proline; Ritonavir | 2022 |
Why scientists are racing to develop more COVID antivirals.
Topics: Adenosine Monophosphate; Administration, Oral; Alanine; Antiviral Agents; COVID-19; COVID-19 Drug Treatment; COVID-19 Vaccines; Cytidine; Drug Approval; Drug Combinations; Drug Development; Drug Resistance, Viral; Drug Therapy, Combination; Hospitalization; Humans; Hydroxylamines; Lactams; Leucine; Medication Adherence; Molecular Targeted Therapy; Mutagenesis; Nitriles; Proline; Public-Private Sector Partnerships; Research Personnel; Ritonavir; SARS-CoV-2 | 2022 |
Remdesivir, Molnupiravir and Nirmatrelvir remain active against SARS-CoV-2 Omicron and other variants of concern.
Topics: Adenosine; Adenosine Monophosphate; Alanine; Animals; Antiviral Agents; Cell Line; Chlorocebus aethiops; Coronavirus 3C Proteases; COVID-19 Drug Treatment; Cytidine; Humans; Hydroxylamines; Lactams; Leucine; Microbial Sensitivity Tests; Nitriles; Proline; RNA-Dependent RNA Polymerase; SARS-CoV-2; Vero Cells; Virus Replication | 2022 |
COVID-19: LMICs need antivirals as well as vaccines.
Topics: Antiviral Agents; COVID-19; COVID-19 Drug Treatment; COVID-19 Vaccines; Cytidine; Developed Countries; Developing Countries; Drug Costs; Healthcare Disparities; Hospitalization; Humans; Hydroxylamines; Lactams; Leucine; Licensure; Nitriles; Proline | 2022 |
Treatment of COVID-19 in high-risk outpatients.
Topics: Adenosine Monophosphate; Alanine; Ambulatory Care; Antibodies, Monoclonal, Humanized; Antibodies, Neutralizing; Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Cytidine; Drug Combinations; Humans; Hydroxylamines; Lactams; Leucine; Nitriles; Outpatients; Proline; Ritonavir; Treatment Outcome | 2022 |
Hundreds of COVID trials could provide a deluge of new drugs.
Topics: Adenosine Monophosphate; Administration, Oral; Alanine; Animals; Anti-Inflammatory Agents; Antibodies, Monoclonal; Antibodies, Neutralizing; Antiviral Agents; Clinical Trials as Topic; COVID-19; COVID-19 Drug Treatment; COVID-19 Vaccines; Cytidine; Depsipeptides; Dexamethasone; Drug Combinations; Drug Repositioning; Drug Synergism; Esters; Guanidines; Hospitalization; Host-Pathogen Interactions; Humans; Hydroxylamines; Internationality; Lactams; Leucine; Mice; National Institutes of Health (U.S.); Nitriles; Peptide Elongation Factor 1; Peptides, Cyclic; Proline; Protease Inhibitors; Ritonavir; RNA-Dependent RNA Polymerase; SARS-CoV-2; Serine Endopeptidases; Sodium-Glucose Transporter 2 Inhibitors; United States; Virus Replication | 2022 |
Characterization and antiviral susceptibility of SARS-CoV-2 Omicron BA.2.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neutralizing; Antibodies, Viral; Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Cricetinae; Cytidine; Drug Combinations; Hydroxylamines; Indazoles; Lactams; Leucine; Mice; Nitriles; Proline; SARS-CoV-2; Spike Glycoprotein, Coronavirus; Triazines; Triazoles | 2022 |
Editorial: Rebound COVID-19 and Cessation of Antiviral Treatment for SARS-CoV-2 with Paxlovid and Molnupiravir.
Topics: Antiviral Agents; COVID-19 Drug Treatment; Cytidine; Drug Combinations; Humans; Hydroxylamines; Lactams; Leucine; Nitriles; Proline; Ritonavir; SARS-CoV-2 | 2022 |